Literature DB >> 21238899

Serum surrogate markers of liver fibrosis in primary biliary cirrhosis.

Argiro Voumvouraki1, Mairi Koulentaki, George Notas, Ourania Sfakianaki, Elias Kouroumalis.   

Abstract

BACKGROUND: Hyaluronan, leptin, laminin and collagen IV have been used extensively for the assessment of liver fibrosis. The aim of this study was to assay these markers in the peripheral and hepatic vein blood of primary biliary cirrhosis (PBC) patients and to study their ability to discriminate early from advanced disease.
METHODS: Sera from 62 PBC patients were compared to 60 controls, 44 chronic Hepatitis C, 38 hepatocellular carcinoma and 34 viral cirrhosis patients. Serum from the hepatic vein of 15 cirrhotic PBC patients and 17 patients with viral cirrhosis was also assayed.
RESULTS: All disease groups had significantly increased levels of hyaluronan and collagen IV, compared to controls, while laminin was significantly increased only in viral cirrhosis. Hyaluronan levels were statistically different between early (54.5 ng/ml; 95%CI 27.3-426.9) and late PBC (154.5 ng/ml; 95%CI 55.3-764.4, p<0.05). The area under the curve (AUC) for the identification of late PBC was 0.74 for hyaluronan, 0.63 for leptin, 0.59 for laminin and 0.70 for collagen IV. Hyaluronan had high sensitivity and NPV in identifying late stages of PBC (96% and 90%, respectively). Short term UDCA had no effect on these markers.
CONCLUSION: No single measurement can differentiate between advanced and early fibrosis in PBC. However serum hyaluronan is a promising single serum marker for longitudinal studies in PBC.
Copyright © 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21238899     DOI: 10.1016/j.ejim.2010.10.002

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  7 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Leptin Enhances Hepatic Fibrosis and Inflammation in a Mouse Model of Cholestasis.

Authors:  Anca D Petrescu; Stephanie Grant; Elaina Williams; Su Yeon An; Nikhil Seth; Mark Shell; Tyson Amundsen; Christopher Tan; Yusra Nadeem; Matthew Tjahja; Lancaster Weld; Christopher S Chu; Julie Venter; Gabriel Frampton; Matthew McMillin; Sharon DeMorrow
Journal:  Am J Pathol       Date:  2021-12-08       Impact factor: 4.307

3.  Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial.

Authors:  Xiao-Li Pan; Li Zhao; Liang Li; Ai-Hua Li; Jin Ye; Ling Yang; Ke-Shu Xu; Xiao-Hua Hou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

Review 4.  Biomarkers for primary biliary cholangitis: current perspectives.

Authors:  Elias Kouroumalis; Demetrius Samonakis; Argyro Voumvouraki
Journal:  Hepat Med       Date:  2018-06-18

5.  Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies.

Authors:  Danielle Cristiane Baldo; Alessandra Dellavance; Maria Lucia Gomes Ferraz; Luis Eduardo C Andrade
Journal:  Auto Immun Highlights       Date:  2019-10-31

6.  The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis.

Authors:  Lilong Zhang; Qihang Yuan; Man Li; Dongqi Chai; Wenhong Deng; Weixing Wang
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

Review 7.  Recent advances in the diagnosis and treatment of primary biliary cholangitis.

Authors:  Ying-Qiu Huang
Journal:  World J Hepatol       Date:  2016-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.